PONVORY

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Italy, Lithuania, Poland, Romania, Spain, UK.

Active ingredients

The drug PONVORY contains one active pharmaceutical ingredient (API):

1	Ponesimod UNII 5G7AKV2MKP - PONESIMOD
	Ponesimod is a sphingosine 1-phosphate (S1P) receptor 1 modulator. Ponesimod binds with high affinity to S1P receptor 1 located on lymphocytes. It blocks the capacity of lymphocytes to egress from lymph nodes reducing the number of lymphocytes in peripheral blood. The mechanism by which it exerts therapeutic effects in multiple sclerosis may involve reduction of lymphocyte migration into the central nervous system.
	Read more about Ponesimod

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PONVORY Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AE04		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AE Sphingosine-1-phosphate (S1P) receptor modulators
Discover more medicines within L04AE04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1856842, 1863402
ES	Centro de información online de medicamentos de la AEMPS	1211550001, 1211550002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	079729, 545880
FR	Base de données publique des médicaments	61715282, 62056415
IE	Health Products Regulatory Authority	89129, 89130
IT	Agenzia del Farmaco	049544012, 049544024, 049544036
LT	Valstybinė vaistų kontrolės tarnyba	1092405, 1092687
PL	Rejestru Produktów Leczniczych	100455240, 100455257
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69196001, W69197001